Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07538583 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Phase 2/3 Clinical Study of QRX003 Lotion in Subjects With Netherton Syndrome

StatusRecruiting
PhasePhase 2/3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial sites expanded: 5 → 8 locations
    • Eligibility criteria expanded, about 16 words
    • Secondary endpoints: details revised at 1 of 3 entries
  2. Site contacts updated at 5 of 5 sitesv2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a multicenter, open-label study to evaluate the safety, tolerability, and efficacy of 4% QRX003 lotion applied twice daily (BID) for 12 weeks to Netherton syndrome (NS) diseased skin in all affected areas of the body excluding the scalp (the Treatment Area), totaling approximately 50% Body Surface Area (BSA) or more.
Trial Details
NCT Number NCT07538583
Lead Sponsor Quoin Pharmaceuticals
Conditions
(from sponsor)		 Netherton Syndrome
Related terms Netherton Syndrome
Enrollment 16 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov